Хепатоцелуларни карцином (Serbian Wikipedia)
Analysis of information sources in references of the Wikipedia article "Хепатоцелуларни карцином" in Serbian language version.
refsWebsite
Global rank
Serbian rank
11th place
23rd place
6th place
5th place
5th place
12th place
low place
246th place
low place
low place
102nd place
266th place
621st place
705th place
18th place
28th place
archive.org
- Bruix, J.; Llovet, J. M. (2002). „Prognostic prediction and treatment strategy in hepatocellular carcinoma”. Hepatology. 35 (3): 519—24. PMID 11870363. S2CID 44358277. doi:10.1053/jhep.2002.32089..
- Befeler, A. S.; Di Bisceglie, A. M. (2002). „Hepatocellular carcinoma: diagnosis and treat-ment”. Gastroenterology. 122 (6): 1609—19. PMID 12016426. doi:10.1053/gast.2002.33411..
- Ozturk, M. (1999). „Genetic aspects of hepatocellular carcinogenesis”. Semin Liver Dis. 19 (3): 235—42. PMID 10518303. S2CID 31317381. doi:10.1055/s-2007-1007113. hdl:11693/25189..
- Bergsland, E. K. (2001). „Molecular mechanisms underlying the development of hepatocellular carcinoma”. Semin Oncol. 28 (5): 521—31. PMID 11685745. doi:10.1016/S0093-7754(01)90145-9..
- Suriawinata, A.; Xu, R. (2004). „An update on the molecular genetics of hepatocellular carcinoma”. Semin Liver Dis. 24 (1): 77—88. PMID 15085488. S2CID 260319631. doi:10.1055/s-2004-823102..
- Satyanarayana, A.; Manns, M. P.; Rudolph, K. L. (2004). „Telomeres and telomerase: a dual role in hepatocarcinogenesis”. Hepatology. 40 (2): 276—83. PMID 15368430. S2CID 29674303. doi:10.1002/hep.20308..
- Velázquez, R. F.; Rodríguez, M.; Navascués, C. A.; Linares, A.; Pérez, R.; Sotorríos, N. G.; Martínez, I.; Rodrigo, L. (2003). „Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis”. Hepatology. 37 (3): 520—27. PMID 12601348. S2CID 7230481. doi:10.1053/jhep.2003.50093..
- Ming, L.; Thorgeirsson, S. S.; Gail, M. H.; Lu, P.; Harris, C. C.; Wang, N.; Shao, Y.; Wu, Z.; Liu, G.; Wang, X.; Sun, Z. (2002). „Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China”. Hepatology. 36 (5): 1214—20. PMID 12395332. S2CID 41031250. doi:10.1053/jhep.2002.36366..
- Hassan, M. M.; Hwang, L. Y.; Hatten, C. J.; Swaim, M.; Li, D.; Abbruzzese, J. L.; Beasley, P.; Patt, Y. Z. (2002). „Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus”. Hepatology. 36 (5): 1206—13. PMID 12395331. S2CID 26467609. doi:10.1053/jhep.2002.36780..
- Yano, Y.; Yamashita, F.; Sumie, S.; Ando, E.; Fukumori, K.; Kiyama, M.; Oyama, T.; Kuroki, S.; Kato, O.; Yamamoto, H.; Tanaka, M.; Sata, M. (2002). „Clinical features of hepatocellular carcinoma seronegative for both HBsAg and anti-HCV antibody but positive for antiHBc antibody in Japan”. Am J Gastroenterol. 97 (1): 156—61. PMID 11808941. S2CID 52849568. doi:10.1111/j.1572-0241.2002.05440.x..
- Pollicino, T.; Squadrito, G.; Cerenzia, G.; Cacciola, I.; Raffa, G.; Craxi, A.; Farinati, F.; Missale, G.; Smedile, A.; Tiribelli, C.; Villa, E.; Raimondo, G. (2004). „Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection”. Gastroenterology. 126 (1): 102—10. PMID 14699492. doi:10.1053/j.gastro.2003.10.048..
- Simonetti, R. G.; Liberati, A.; Angiolini, C.; Pagliaro, L. (1997). „Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials”. Ann Oncol. 8 (2): 117—36. PMID 9093719. doi:10.1023/A:1008285123736..
- Yuen, M. F.; Poon, R. T.; Lai, C. L.; Fan, S. T.; Lo, C. M.; Wong, K. W.; Wong, W. M.; Wong, B. C. (2002). „A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma”. Hepatology. 36 (3): 687—91. PMID 12198662. S2CID 6394987. doi:10.1053/jhep.2002.35071..
- Cillo, U.; Vitale, A.; Bassanello, M.; Boccagni, P.; Brolese, A.; Zanus, G.; Burra, P.; Fagiuoli, S.; Farinati, F.; Rugge, M.; d'Amico, D. F. (2004). „Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma”. Annals of Surgery. 239 (2): 150—9. PMC 1356206
. PMID 14745321. doi:10.1097/01.sla.0000109146.72827.76..
doi.org
- Shetty, Shrimati; Sharma, Nitika; Ghosh, Kanjaksha (2016). „Epidemiology of hepatocellular carcinoma (HCC) in hemophilia”. Critical Reviews in Oncology/Hematology. 99: 129—133. ISSN 1040-8428. PMID 26754251. doi:10.1016/j.critrevonc.2015.12.009.
- Forner, Alejandro; Llovet, Josep M.; Bruix, Jordi (2012). „Hepatocellular carcinoma”. The Lancet. 379 (9822): 1245—1255. PMID 22353262. S2CID 24927898. doi:10.1016/S0140-6736(11)61347-0.
- Bruix, J.; Llovet, J. M. (2002). „Prognostic prediction and treatment strategy in hepatocellular carcinoma”. Hepatology. 35 (3): 519—24. PMID 11870363. S2CID 44358277. doi:10.1053/jhep.2002.32089..
- Befeler, A. S.; Di Bisceglie, A. M. (2002). „Hepatocellular carcinoma: diagnosis and treat-ment”. Gastroenterology. 122 (6): 1609—19. PMID 12016426. doi:10.1053/gast.2002.33411..
- Deuffic, S.; Poynard, T.; Buffat, L.; Valleron, A. J. (1998). „Trends in primary liver cancer”. Lancet. 351 (9097): 214—5. PMID 9449893. S2CID 5263951. doi:10.1016/S0140-6736(05)78179-4.
- El-Serag, H. B.; Mason, A. C. (1999). „Rising incidence of hepatocellular carcinoma in the United States”. New England Journal of Medicine. 340 (10): 745—50. PMID 10072408. doi:10.1056/NEJM199903113401001..
- Ozturk, M. (1999). „Genetic aspects of hepatocellular carcinogenesis”. Semin Liver Dis. 19 (3): 235—42. PMID 10518303. S2CID 31317381. doi:10.1055/s-2007-1007113. hdl:11693/25189..
- Bergsland, E. K. (2001). „Molecular mechanisms underlying the development of hepatocellular carcinoma”. Semin Oncol. 28 (5): 521—31. PMID 11685745. doi:10.1016/S0093-7754(01)90145-9..
- Thorgeirsson, S. S.; Grisham, J. W. (2002). „Molecular pathogenesis of human hepatocellular carcinoma”. Nat Genet. 31 (4): 339—46. PMID 12149612. S2CID 270102. doi:10.1038/ng0802-339..
- Block, T. M.; Mehta, A. S.; Fimmel, C. J.; Jordan, R. (2003). „Molecular viral oncology of hepa-tocellular carcinoma”. Oncogene. 22 (33): 5093—107. PMID 12910247. S2CID 36007702. doi:10.1038/sj.onc.1206557..
- Suriawinata, A.; Xu, R. (2004). „An update on the molecular genetics of hepatocellular carcinoma”. Semin Liver Dis. 24 (1): 77—88. PMID 15085488. S2CID 260319631. doi:10.1055/s-2004-823102..
- Satyanarayana, A.; Manns, M. P.; Rudolph, K. L. (2004). „Telomeres and telomerase: a dual role in hepatocarcinogenesis”. Hepatology. 40 (2): 276—83. PMID 15368430. S2CID 29674303. doi:10.1002/hep.20308..
- Velázquez, R. F.; Rodríguez, M.; Navascués, C. A.; Linares, A.; Pérez, R.; Sotorríos, N. G.; Martínez, I.; Rodrigo, L. (2003). „Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis”. Hepatology. 37 (3): 520—27. PMID 12601348. S2CID 7230481. doi:10.1053/jhep.2003.50093..
- Ohata, K.; Hamasaki, K.; Toriyama, K.; Matsumoto, K.; Saeki, A.; Yanagi, K.; Abiru, S.; Nakagawa, Y.; Shigeno, M.; Miyazoe, S.; Ichikawa, T.; Ishikawa, H.; Nakao, K.; Eguchi, K. (2003). „Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection”. Cancer. 97 (12): 3036—43. PMID 12784339. S2CID 26074534. doi:10.1002/cncr.11427..
- Ming, L.; Thorgeirsson, S. S.; Gail, M. H.; Lu, P.; Harris, C. C.; Wang, N.; Shao, Y.; Wu, Z.; Liu, G.; Wang, X.; Sun, Z. (2002). „Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China”. Hepatology. 36 (5): 1214—20. PMID 12395332. S2CID 41031250. doi:10.1053/jhep.2002.36366..
- Hassan, M. M.; Hwang, L. Y.; Hatten, C. J.; Swaim, M.; Li, D.; Abbruzzese, J. L.; Beasley, P.; Patt, Y. Z. (2002). „Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus”. Hepatology. 36 (5): 1206—13. PMID 12395331. S2CID 26467609. doi:10.1053/jhep.2002.36780..
- Yano, Y.; Yamashita, F.; Sumie, S.; Ando, E.; Fukumori, K.; Kiyama, M.; Oyama, T.; Kuroki, S.; Kato, O.; Yamamoto, H.; Tanaka, M.; Sata, M. (2002). „Clinical features of hepatocellular carcinoma seronegative for both HBsAg and anti-HCV antibody but positive for antiHBc antibody in Japan”. Am J Gastroenterol. 97 (1): 156—61. PMID 11808941. S2CID 52849568. doi:10.1111/j.1572-0241.2002.05440.x..
- Pollicino, T.; Squadrito, G.; Cerenzia, G.; Cacciola, I.; Raffa, G.; Craxi, A.; Farinati, F.; Missale, G.; Smedile, A.; Tiribelli, C.; Villa, E.; Raimondo, G. (2004). „Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection”. Gastroenterology. 126 (1): 102—10. PMID 14699492. doi:10.1053/j.gastro.2003.10.048..
- Shiha G, Ibrahim A, Helmy A, Sarin SK, Omata M, Kumar A, et al. . "Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update". Hepatology International. Shiha, G.; et al. (јануар 2017). „Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: A 2016 update”. Hepatology International. 11 (1): 1—30. PMID 27714681. S2CID 34896412. doi:10.1007/s12072-016-9760-3..
- Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. . "The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases" (PDF). Hepatology. Chalasani, N.; Younossi, Z.; Lavine, J. E.; Charlton, M.; Cusi, K.; Rinella, M.; Harrison, S. A.; Brunt, E. M.; Sanyal, A. J. (јануар 2018). „The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases”. Hepatology International. 67 (1): 328—357. PMID 28714183. S2CID 4120649. doi:10.1002/hep.29367..
- Marrero, Jorge A.; Kulik, Laura M.; Sirlin, Claude B.; Zhu, Andrew X.; Finn, Richard S.; Abecassis, Michael M.; Roberts, Lewis R.; Heimbach, Julie K. (2018). „Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases”. Hepatology. 68 (2): 723—750. PMID 29624699. S2CID 4666537. doi:10.1002/hep.29913.
- Ma, K. W.; Cheung, T. T. (2017). „Surgical resection of localized hepatocellular carcinoma: Patient selection and special consideration”. Journal of Hepatocellular Carcinoma. 4: 1—9. PMC 5207474 . PMID 28097107. doi:10.2147/JHC.S96085 ..
- Ang, S. F.; Ng, E. S.; Li, H.; Ong, Y. H.; Choo, S. P.; Ngeow, J.; Toh, H. C.; Lim, K. H.; Yap, H. Y.; Tan, C. K.; Ooi, L. L.; Cheow, P. C.; Chung, A. Y.; Chow, P. K.; Foo, K. F.; Tan, M. H. (2015). „The Singapore Liver Cancer Recurrence (SLICER) Score for relapse prediction in patients with surgically resected hepatocellular carcinoma”. PLOS ONE. 10 (4): e0118658. Bibcode:2015PLoSO..1018658A. PMC 4382157 . PMID 25830231. doi:10.1371/journal.pone.0118658 .
- Simonetti, R. G.; Liberati, A.; Angiolini, C.; Pagliaro, L. (1997). „Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials”. Ann Oncol. 8 (2): 117—36. PMID 9093719. doi:10.1023/A:1008285123736..
- Yuen, M. F.; Poon, R. T.; Lai, C. L.; Fan, S. T.; Lo, C. M.; Wong, K. W.; Wong, W. M.; Wong, B. C. (2002). „A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma”. Hepatology. 36 (3): 687—91. PMID 12198662. S2CID 6394987. doi:10.1053/jhep.2002.35071..
- Hsu, C.; Chen, C. N.; Chen, L. T.; Wu, C. Y.; Yang, P. M.; Lai, M. Y.; Lee, P. H.; Cheng, A. L. (2003). „Low-dose thalidomide treatment for advanced hepatocellular carcinoma”. Oncology. 65 (3): 242—9. PMID 14657598. S2CID 25528287. doi:10.1159/000074477..
- Villa, E.; Ferretti, I.; Grottola, A.; Buttafoco, P.; Buono, M. G.; Giannini, F.; Manno, M.; Bertani, H.; Dugani, A.; Manenti, F. (2001). „Hormonal therapy with megestrol in inoper-able hepatocellular carcinoma characterized by variant oestrogen receptors”. Br J Cancer. 84 (7): 881—5. PMC 2363845 . PMID 11286465. doi:10.1054/bjoc.2000.1534..
- Wigg, A. J.; Palumbo, K.; Wigg, D. R. (2010). „Radiotherapy for hepatocellular carcinoma: Systematic review of radiobiology and modeling projections indicate reconsideration of its use”. Journal of Gastroenterology and Hepatology. 25 (4): 664—671. PMID 20074152. S2CID 46110083. doi:10.1111/j.1440-1746.2009.06126.x..
- Kulik, L. M.; Carr, B. I.; Mulcahy, M. F.; Lewandowski, R. J.; Atassi, B.; Ryu, R. K.; Sato, K. T.; Benson a, 3rd; Nemcek Jr, A. A.; Gates, V. L.; Abecassis, M.; Omary, R. A.; Salem, R. (2008). „Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis”. Hepatology (Baltimore, Md.). 47 (1): 71—81. PMID 18027884. S2CID 27591331. doi:10.1002/hep.21980..
- Balogh, J.; Victor d, 3rd; Asham, E. H.; Burroughs, S. G.; Boktour, M.; Saharia, A.; Li, X.; Ghobrial, R. M.; Monsour Jr, H. P. (2016). „Hepatocellular carcinoma: A review”. Journal of Hepatocellular Carcinoma. 3: 41—53. PMC 5063561 . PMID 27785449. doi:10.2147/JHC.S61146 ..
- Fan, Jia; Yang, Guang-Shun; Fu, Zhi-Ren; Peng, Zhi-Hai; Xia, Qiang; Peng, Chen-Hong; Qian, Jian-Ming; Zhou, Jian; Xu, Yang; et al. (2009). „Liver transplantation outcomes in 1,078 hepatocellular carcinoma patients: a multi-center experience in Shanghai, China”. Journal of Cancer Research and Clinical Oncology. 135 (10): 1403—1412. PMID 19381688. S2CID 1216580. doi:10.1007/s00432-009-0584-6..
- Vitale, A.; Gringeri, E.; Valmasoni, M.; d'Amico, F.; Carraro, A.; Pauletto, A.; d'Amico, F. J.; Polacco, M.; d'Amico, D. F.; Cillo, U. (2007). „Long-term results of liver transplantation for hepatocellular carcinoma: An update of the University of Padova experience”. Transplantation Proceedings. 39 (6): 1892—1894. PMID 17692645. doi:10.1016/j.transproceed.2007.05.031..
- Obed, Aiman; Tsui, Tung-Yu; Schnitzbauer, Andreas A.; Obed, Manal; Schlitt, Hans J.; Becker, Heinz; Lorf, Thomas (2009). „Liver Transplantation for Hepatocellular Carcinoma: Need for a New Patient Selection Strategy: Reply”. Langenbeck's Archives of Surgery. 393 (2): 141—147. PMC 3085731 . PMID 18043937. doi:10.1007/s00423-007-0250-x.
- Michelakos, T; Xourafas, D; Qadan, M; Pieretti-Vanmarcke, R; Cai, L; Patel, MS; Adler, JT; Fontan, F; Basit, U; Vagefi, PA; Elias, N; Tanabe, KK; Berger, D; Yeh, H; Markmann, JF; Chang, DC; Ferrone, CR (јун 2019). „Hepatocellular Carcinoma in Transplantable Child-Pugh A Cirrhotics: Should Cost Affect Resection vs Transplantation?”. Journal of Gastrointestinal Surgery. 23 (6): 1135—1142. PMID 30218342. S2CID 52275656. doi:10.1007/s11605-018-3946-z..
- Cillo, U.; Vitale, A.; Bassanello, M.; Boccagni, P.; Brolese, A.; Zanus, G.; Burra, P.; Fagiuoli, S.; Farinati, F.; Rugge, M.; d'Amico, D. F. (2004). „Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma”. Annals of Surgery. 239 (2): 150—9. PMC 1356206 . PMID 14745321. doi:10.1097/01.sla.0000109146.72827.76..
handle.net
hdl.handle.net
- Ozturk, M. (1999). „Genetic aspects of hepatocellular carcinogenesis”. Semin Liver Dis. 19 (3): 235—42. PMID 10518303. S2CID 31317381. doi:10.1055/s-2007-1007113. hdl:11693/25189..
harvard.edu
adsabs.harvard.edu
- Ang, S. F.; Ng, E. S.; Li, H.; Ong, Y. H.; Choo, S. P.; Ngeow, J.; Toh, H. C.; Lim, K. H.; Yap, H. Y.; Tan, C. K.; Ooi, L. L.; Cheow, P. C.; Chung, A. Y.; Chow, P. K.; Foo, K. F.; Tan, M. H. (2015). „The Singapore Liver Cancer Recurrence (SLICER) Score for relapse prediction in patients with surgically resected hepatocellular carcinoma”. PLOS ONE. 10 (4): e0118658. Bibcode:2015PLoSO..1018658A. PMC 4382157 . PMID 25830231. doi:10.1371/journal.pone.0118658 .
iarc.fr
gco.iarc.fr
- Cancer (IARC), The International Agency for Research on. „Global Cancer Observatory”. gco.iarc.fr (на језику: енглески). Приступљено 2023-01-23.
nih.gov
ncbi.nlm.nih.gov
- Shetty, Shrimati; Sharma, Nitika; Ghosh, Kanjaksha (2016). „Epidemiology of hepatocellular carcinoma (HCC) in hemophilia”. Critical Reviews in Oncology/Hematology. 99: 129—133. ISSN 1040-8428. PMID 26754251. doi:10.1016/j.critrevonc.2015.12.009.
- Forner, Alejandro; Llovet, Josep M.; Bruix, Jordi (2012). „Hepatocellular carcinoma”. The Lancet. 379 (9822): 1245—1255. PMID 22353262. S2CID 24927898. doi:10.1016/S0140-6736(11)61347-0.
- Bruix, J.; Llovet, J. M. (2002). „Prognostic prediction and treatment strategy in hepatocellular carcinoma”. Hepatology. 35 (3): 519—24. PMID 11870363. S2CID 44358277. doi:10.1053/jhep.2002.32089..
- Befeler, A. S.; Di Bisceglie, A. M. (2002). „Hepatocellular carcinoma: diagnosis and treat-ment”. Gastroenterology. 122 (6): 1609—19. PMID 12016426. doi:10.1053/gast.2002.33411..
- Deuffic, S.; Poynard, T.; Buffat, L.; Valleron, A. J. (1998). „Trends in primary liver cancer”. Lancet. 351 (9097): 214—5. PMID 9449893. S2CID 5263951. doi:10.1016/S0140-6736(05)78179-4.
- El-Serag, H. B.; Mason, A. C. (1999). „Rising incidence of hepatocellular carcinoma in the United States”. New England Journal of Medicine. 340 (10): 745—50. PMID 10072408. doi:10.1056/NEJM199903113401001..
- Ozturk, M. (1999). „Genetic aspects of hepatocellular carcinogenesis”. Semin Liver Dis. 19 (3): 235—42. PMID 10518303. S2CID 31317381. doi:10.1055/s-2007-1007113. hdl:11693/25189..
- Bergsland, E. K. (2001). „Molecular mechanisms underlying the development of hepatocellular carcinoma”. Semin Oncol. 28 (5): 521—31. PMID 11685745. doi:10.1016/S0093-7754(01)90145-9..
- Thorgeirsson, S. S.; Grisham, J. W. (2002). „Molecular pathogenesis of human hepatocellular carcinoma”. Nat Genet. 31 (4): 339—46. PMID 12149612. S2CID 270102. doi:10.1038/ng0802-339..
- Block, T. M.; Mehta, A. S.; Fimmel, C. J.; Jordan, R. (2003). „Molecular viral oncology of hepa-tocellular carcinoma”. Oncogene. 22 (33): 5093—107. PMID 12910247. S2CID 36007702. doi:10.1038/sj.onc.1206557..
- Suriawinata, A.; Xu, R. (2004). „An update on the molecular genetics of hepatocellular carcinoma”. Semin Liver Dis. 24 (1): 77—88. PMID 15085488. S2CID 260319631. doi:10.1055/s-2004-823102..
- Satyanarayana, A.; Manns, M. P.; Rudolph, K. L. (2004). „Telomeres and telomerase: a dual role in hepatocarcinogenesis”. Hepatology. 40 (2): 276—83. PMID 15368430. S2CID 29674303. doi:10.1002/hep.20308..
- Velázquez, R. F.; Rodríguez, M.; Navascués, C. A.; Linares, A.; Pérez, R.; Sotorríos, N. G.; Martínez, I.; Rodrigo, L. (2003). „Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis”. Hepatology. 37 (3): 520—27. PMID 12601348. S2CID 7230481. doi:10.1053/jhep.2003.50093..
- Ohata, K.; Hamasaki, K.; Toriyama, K.; Matsumoto, K.; Saeki, A.; Yanagi, K.; Abiru, S.; Nakagawa, Y.; Shigeno, M.; Miyazoe, S.; Ichikawa, T.; Ishikawa, H.; Nakao, K.; Eguchi, K. (2003). „Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection”. Cancer. 97 (12): 3036—43. PMID 12784339. S2CID 26074534. doi:10.1002/cncr.11427..
- Ming, L.; Thorgeirsson, S. S.; Gail, M. H.; Lu, P.; Harris, C. C.; Wang, N.; Shao, Y.; Wu, Z.; Liu, G.; Wang, X.; Sun, Z. (2002). „Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China”. Hepatology. 36 (5): 1214—20. PMID 12395332. S2CID 41031250. doi:10.1053/jhep.2002.36366..
- Hassan, M. M.; Hwang, L. Y.; Hatten, C. J.; Swaim, M.; Li, D.; Abbruzzese, J. L.; Beasley, P.; Patt, Y. Z. (2002). „Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus”. Hepatology. 36 (5): 1206—13. PMID 12395331. S2CID 26467609. doi:10.1053/jhep.2002.36780..
- Yano, Y.; Yamashita, F.; Sumie, S.; Ando, E.; Fukumori, K.; Kiyama, M.; Oyama, T.; Kuroki, S.; Kato, O.; Yamamoto, H.; Tanaka, M.; Sata, M. (2002). „Clinical features of hepatocellular carcinoma seronegative for both HBsAg and anti-HCV antibody but positive for antiHBc antibody in Japan”. Am J Gastroenterol. 97 (1): 156—61. PMID 11808941. S2CID 52849568. doi:10.1111/j.1572-0241.2002.05440.x..
- Pollicino, T.; Squadrito, G.; Cerenzia, G.; Cacciola, I.; Raffa, G.; Craxi, A.; Farinati, F.; Missale, G.; Smedile, A.; Tiribelli, C.; Villa, E.; Raimondo, G. (2004). „Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection”. Gastroenterology. 126 (1): 102—10. PMID 14699492. doi:10.1053/j.gastro.2003.10.048..
- Shiha G, Ibrahim A, Helmy A, Sarin SK, Omata M, Kumar A, et al. . "Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update". Hepatology International. Shiha, G.; et al. (јануар 2017). „Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: A 2016 update”. Hepatology International. 11 (1): 1—30. PMID 27714681. S2CID 34896412. doi:10.1007/s12072-016-9760-3..
- Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. . "The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases" (PDF). Hepatology. Chalasani, N.; Younossi, Z.; Lavine, J. E.; Charlton, M.; Cusi, K.; Rinella, M.; Harrison, S. A.; Brunt, E. M.; Sanyal, A. J. (јануар 2018). „The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases”. Hepatology International. 67 (1): 328—357. PMID 28714183. S2CID 4120649. doi:10.1002/hep.29367..
- Marrero, Jorge A.; Kulik, Laura M.; Sirlin, Claude B.; Zhu, Andrew X.; Finn, Richard S.; Abecassis, Michael M.; Roberts, Lewis R.; Heimbach, Julie K. (2018). „Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases”. Hepatology. 68 (2): 723—750. PMID 29624699. S2CID 4666537. doi:10.1002/hep.29913.
- Ma, K. W.; Cheung, T. T. (2017). „Surgical resection of localized hepatocellular carcinoma: Patient selection and special consideration”. Journal of Hepatocellular Carcinoma. 4: 1—9. PMC 5207474 . PMID 28097107. doi:10.2147/JHC.S96085 ..
- Ang, S. F.; Ng, E. S.; Li, H.; Ong, Y. H.; Choo, S. P.; Ngeow, J.; Toh, H. C.; Lim, K. H.; Yap, H. Y.; Tan, C. K.; Ooi, L. L.; Cheow, P. C.; Chung, A. Y.; Chow, P. K.; Foo, K. F.; Tan, M. H. (2015). „The Singapore Liver Cancer Recurrence (SLICER) Score for relapse prediction in patients with surgically resected hepatocellular carcinoma”. PLOS ONE. 10 (4): e0118658. Bibcode:2015PLoSO..1018658A. PMC 4382157 . PMID 25830231. doi:10.1371/journal.pone.0118658 .
- Simonetti, R. G.; Liberati, A.; Angiolini, C.; Pagliaro, L. (1997). „Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials”. Ann Oncol. 8 (2): 117—36. PMID 9093719. doi:10.1023/A:1008285123736..
- Yuen, M. F.; Poon, R. T.; Lai, C. L.; Fan, S. T.; Lo, C. M.; Wong, K. W.; Wong, W. M.; Wong, B. C. (2002). „A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma”. Hepatology. 36 (3): 687—91. PMID 12198662. S2CID 6394987. doi:10.1053/jhep.2002.35071..
- Hsu, C.; Chen, C. N.; Chen, L. T.; Wu, C. Y.; Yang, P. M.; Lai, M. Y.; Lee, P. H.; Cheng, A. L. (2003). „Low-dose thalidomide treatment for advanced hepatocellular carcinoma”. Oncology. 65 (3): 242—9. PMID 14657598. S2CID 25528287. doi:10.1159/000074477..
- Villa, E.; Ferretti, I.; Grottola, A.; Buttafoco, P.; Buono, M. G.; Giannini, F.; Manno, M.; Bertani, H.; Dugani, A.; Manenti, F. (2001). „Hormonal therapy with megestrol in inoper-able hepatocellular carcinoma characterized by variant oestrogen receptors”. Br J Cancer. 84 (7): 881—5. PMC 2363845 . PMID 11286465. doi:10.1054/bjoc.2000.1534..
- Wigg, A. J.; Palumbo, K.; Wigg, D. R. (2010). „Radiotherapy for hepatocellular carcinoma: Systematic review of radiobiology and modeling projections indicate reconsideration of its use”. Journal of Gastroenterology and Hepatology. 25 (4): 664—671. PMID 20074152. S2CID 46110083. doi:10.1111/j.1440-1746.2009.06126.x..
- Kulik, L. M.; Carr, B. I.; Mulcahy, M. F.; Lewandowski, R. J.; Atassi, B.; Ryu, R. K.; Sato, K. T.; Benson a, 3rd; Nemcek Jr, A. A.; Gates, V. L.; Abecassis, M.; Omary, R. A.; Salem, R. (2008). „Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis”. Hepatology (Baltimore, Md.). 47 (1): 71—81. PMID 18027884. S2CID 27591331. doi:10.1002/hep.21980..
- Balogh, J.; Victor d, 3rd; Asham, E. H.; Burroughs, S. G.; Boktour, M.; Saharia, A.; Li, X.; Ghobrial, R. M.; Monsour Jr, H. P. (2016). „Hepatocellular carcinoma: A review”. Journal of Hepatocellular Carcinoma. 3: 41—53. PMC 5063561 . PMID 27785449. doi:10.2147/JHC.S61146 ..
- Fan, Jia; Yang, Guang-Shun; Fu, Zhi-Ren; Peng, Zhi-Hai; Xia, Qiang; Peng, Chen-Hong; Qian, Jian-Ming; Zhou, Jian; Xu, Yang; et al. (2009). „Liver transplantation outcomes in 1,078 hepatocellular carcinoma patients: a multi-center experience in Shanghai, China”. Journal of Cancer Research and Clinical Oncology. 135 (10): 1403—1412. PMID 19381688. S2CID 1216580. doi:10.1007/s00432-009-0584-6..
- Vitale, A.; Gringeri, E.; Valmasoni, M.; d'Amico, F.; Carraro, A.; Pauletto, A.; d'Amico, F. J.; Polacco, M.; d'Amico, D. F.; Cillo, U. (2007). „Long-term results of liver transplantation for hepatocellular carcinoma: An update of the University of Padova experience”. Transplantation Proceedings. 39 (6): 1892—1894. PMID 17692645. doi:10.1016/j.transproceed.2007.05.031..
- Obed, Aiman; Tsui, Tung-Yu; Schnitzbauer, Andreas A.; Obed, Manal; Schlitt, Hans J.; Becker, Heinz; Lorf, Thomas (2009). „Liver Transplantation for Hepatocellular Carcinoma: Need for a New Patient Selection Strategy: Reply”. Langenbeck's Archives of Surgery. 393 (2): 141—147. PMC 3085731 . PMID 18043937. doi:10.1007/s00423-007-0250-x.
- Michelakos, T; Xourafas, D; Qadan, M; Pieretti-Vanmarcke, R; Cai, L; Patel, MS; Adler, JT; Fontan, F; Basit, U; Vagefi, PA; Elias, N; Tanabe, KK; Berger, D; Yeh, H; Markmann, JF; Chang, DC; Ferrone, CR (јун 2019). „Hepatocellular Carcinoma in Transplantable Child-Pugh A Cirrhotics: Should Cost Affect Resection vs Transplantation?”. Journal of Gastrointestinal Surgery. 23 (6): 1135—1142. PMID 30218342. S2CID 52275656. doi:10.1007/s11605-018-3946-z..
- Cillo, U.; Vitale, A.; Bassanello, M.; Boccagni, P.; Brolese, A.; Zanus, G.; Burra, P.; Fagiuoli, S.; Farinati, F.; Rugge, M.; d'Amico, D. F. (2004). „Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma”. Annals of Surgery. 239 (2): 150—9. PMC 1356206 . PMID 14745321. doi:10.1097/01.sla.0000109146.72827.76..
semanticscholar.org
api.semanticscholar.org
- Forner, Alejandro; Llovet, Josep M.; Bruix, Jordi (2012). „Hepatocellular carcinoma”. The Lancet. 379 (9822): 1245—1255. PMID 22353262. S2CID 24927898. doi:10.1016/S0140-6736(11)61347-0.
- Bruix, J.; Llovet, J. M. (2002). „Prognostic prediction and treatment strategy in hepatocellular carcinoma”. Hepatology. 35 (3): 519—24. PMID 11870363. S2CID 44358277. doi:10.1053/jhep.2002.32089..
- Deuffic, S.; Poynard, T.; Buffat, L.; Valleron, A. J. (1998). „Trends in primary liver cancer”. Lancet. 351 (9097): 214—5. PMID 9449893. S2CID 5263951. doi:10.1016/S0140-6736(05)78179-4.
- Ozturk, M. (1999). „Genetic aspects of hepatocellular carcinogenesis”. Semin Liver Dis. 19 (3): 235—42. PMID 10518303. S2CID 31317381. doi:10.1055/s-2007-1007113. hdl:11693/25189..
- Thorgeirsson, S. S.; Grisham, J. W. (2002). „Molecular pathogenesis of human hepatocellular carcinoma”. Nat Genet. 31 (4): 339—46. PMID 12149612. S2CID 270102. doi:10.1038/ng0802-339..
- Block, T. M.; Mehta, A. S.; Fimmel, C. J.; Jordan, R. (2003). „Molecular viral oncology of hepa-tocellular carcinoma”. Oncogene. 22 (33): 5093—107. PMID 12910247. S2CID 36007702. doi:10.1038/sj.onc.1206557..
- Suriawinata, A.; Xu, R. (2004). „An update on the molecular genetics of hepatocellular carcinoma”. Semin Liver Dis. 24 (1): 77—88. PMID 15085488. S2CID 260319631. doi:10.1055/s-2004-823102..
- Satyanarayana, A.; Manns, M. P.; Rudolph, K. L. (2004). „Telomeres and telomerase: a dual role in hepatocarcinogenesis”. Hepatology. 40 (2): 276—83. PMID 15368430. S2CID 29674303. doi:10.1002/hep.20308..
- Velázquez, R. F.; Rodríguez, M.; Navascués, C. A.; Linares, A.; Pérez, R.; Sotorríos, N. G.; Martínez, I.; Rodrigo, L. (2003). „Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis”. Hepatology. 37 (3): 520—27. PMID 12601348. S2CID 7230481. doi:10.1053/jhep.2003.50093..
- Ohata, K.; Hamasaki, K.; Toriyama, K.; Matsumoto, K.; Saeki, A.; Yanagi, K.; Abiru, S.; Nakagawa, Y.; Shigeno, M.; Miyazoe, S.; Ichikawa, T.; Ishikawa, H.; Nakao, K.; Eguchi, K. (2003). „Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection”. Cancer. 97 (12): 3036—43. PMID 12784339. S2CID 26074534. doi:10.1002/cncr.11427..
- Ming, L.; Thorgeirsson, S. S.; Gail, M. H.; Lu, P.; Harris, C. C.; Wang, N.; Shao, Y.; Wu, Z.; Liu, G.; Wang, X.; Sun, Z. (2002). „Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China”. Hepatology. 36 (5): 1214—20. PMID 12395332. S2CID 41031250. doi:10.1053/jhep.2002.36366..
- Hassan, M. M.; Hwang, L. Y.; Hatten, C. J.; Swaim, M.; Li, D.; Abbruzzese, J. L.; Beasley, P.; Patt, Y. Z. (2002). „Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus”. Hepatology. 36 (5): 1206—13. PMID 12395331. S2CID 26467609. doi:10.1053/jhep.2002.36780..
- Yano, Y.; Yamashita, F.; Sumie, S.; Ando, E.; Fukumori, K.; Kiyama, M.; Oyama, T.; Kuroki, S.; Kato, O.; Yamamoto, H.; Tanaka, M.; Sata, M. (2002). „Clinical features of hepatocellular carcinoma seronegative for both HBsAg and anti-HCV antibody but positive for antiHBc antibody in Japan”. Am J Gastroenterol. 97 (1): 156—61. PMID 11808941. S2CID 52849568. doi:10.1111/j.1572-0241.2002.05440.x..
- Shiha G, Ibrahim A, Helmy A, Sarin SK, Omata M, Kumar A, et al. . "Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update". Hepatology International. Shiha, G.; et al. (јануар 2017). „Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: A 2016 update”. Hepatology International. 11 (1): 1—30. PMID 27714681. S2CID 34896412. doi:10.1007/s12072-016-9760-3..
- Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. . "The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases" (PDF). Hepatology. Chalasani, N.; Younossi, Z.; Lavine, J. E.; Charlton, M.; Cusi, K.; Rinella, M.; Harrison, S. A.; Brunt, E. M.; Sanyal, A. J. (јануар 2018). „The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases”. Hepatology International. 67 (1): 328—357. PMID 28714183. S2CID 4120649. doi:10.1002/hep.29367..
- Marrero, Jorge A.; Kulik, Laura M.; Sirlin, Claude B.; Zhu, Andrew X.; Finn, Richard S.; Abecassis, Michael M.; Roberts, Lewis R.; Heimbach, Julie K. (2018). „Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases”. Hepatology. 68 (2): 723—750. PMID 29624699. S2CID 4666537. doi:10.1002/hep.29913.
- Yuen, M. F.; Poon, R. T.; Lai, C. L.; Fan, S. T.; Lo, C. M.; Wong, K. W.; Wong, W. M.; Wong, B. C. (2002). „A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma”. Hepatology. 36 (3): 687—91. PMID 12198662. S2CID 6394987. doi:10.1053/jhep.2002.35071..
- Hsu, C.; Chen, C. N.; Chen, L. T.; Wu, C. Y.; Yang, P. M.; Lai, M. Y.; Lee, P. H.; Cheng, A. L. (2003). „Low-dose thalidomide treatment for advanced hepatocellular carcinoma”. Oncology. 65 (3): 242—9. PMID 14657598. S2CID 25528287. doi:10.1159/000074477..
- Wigg, A. J.; Palumbo, K.; Wigg, D. R. (2010). „Radiotherapy for hepatocellular carcinoma: Systematic review of radiobiology and modeling projections indicate reconsideration of its use”. Journal of Gastroenterology and Hepatology. 25 (4): 664—671. PMID 20074152. S2CID 46110083. doi:10.1111/j.1440-1746.2009.06126.x..
- Kulik, L. M.; Carr, B. I.; Mulcahy, M. F.; Lewandowski, R. J.; Atassi, B.; Ryu, R. K.; Sato, K. T.; Benson a, 3rd; Nemcek Jr, A. A.; Gates, V. L.; Abecassis, M.; Omary, R. A.; Salem, R. (2008). „Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis”. Hepatology (Baltimore, Md.). 47 (1): 71—81. PMID 18027884. S2CID 27591331. doi:10.1002/hep.21980..
- Fan, Jia; Yang, Guang-Shun; Fu, Zhi-Ren; Peng, Zhi-Hai; Xia, Qiang; Peng, Chen-Hong; Qian, Jian-Ming; Zhou, Jian; Xu, Yang; et al. (2009). „Liver transplantation outcomes in 1,078 hepatocellular carcinoma patients: a multi-center experience in Shanghai, China”. Journal of Cancer Research and Clinical Oncology. 135 (10): 1403—1412. PMID 19381688. S2CID 1216580. doi:10.1007/s00432-009-0584-6..
- Michelakos, T; Xourafas, D; Qadan, M; Pieretti-Vanmarcke, R; Cai, L; Patel, MS; Adler, JT; Fontan, F; Basit, U; Vagefi, PA; Elias, N; Tanabe, KK; Berger, D; Yeh, H; Markmann, JF; Chang, DC; Ferrone, CR (јун 2019). „Hepatocellular Carcinoma in Transplantable Child-Pugh A Cirrhotics: Should Cost Affect Resection vs Transplantation?”. Journal of Gastrointestinal Surgery. 23 (6): 1135—1142. PMID 30218342. S2CID 52275656. doi:10.1007/s11605-018-3946-z..
stetoskop.info
- „Hronični virusni hepatitis B i C”. Stetoskop.info (на језику: српски). Приступљено 2023-01-25.
who.int
- „WHO Disease and injury country estimates”. World Health Organization. 2009. Приступљено 11. 11. 2009.
wikipedia.org
en.wikipedia.org
- Ozturk, M. (1999). „Genetic aspects of hepatocellular carcinogenesis”. Semin Liver Dis. 19 (3): 235—42. PMID 10518303. S2CID 31317381. doi:10.1055/s-2007-1007113. hdl:11693/25189..
worldcat.org
zenodo.org
- Thorgeirsson, S. S.; Grisham, J. W. (2002). „Molecular pathogenesis of human hepatocellular carcinoma”. Nat Genet. 31 (4): 339—46. PMID 12149612. S2CID 270102. doi:10.1038/ng0802-339..